179 reports of this reaction
1.5% of all BUPIVACAINE HYDROCHLORIDE reports
#11 most reported adverse reaction
DIZZINESS is the #11 most commonly reported adverse reaction for BUPIVACAINE HYDROCHLORIDE, manufactured by Hospira, Inc.. There are 179 FDA adverse event reports linking BUPIVACAINE HYDROCHLORIDE to DIZZINESS. This represents approximately 1.5% of all 12,011 adverse event reports for this drug.
Patients taking BUPIVACAINE HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for BUPIVACAINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for BUPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 179 FDA reports for BUPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 1.5% of all adverse event reports for BUPIVACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience dizziness while taking BUPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.